Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 48 | 0.91 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 9699
Sealed predictions
- NCAPD2 in dopamine neurons, braak-0.67 (p 0.050) → +0.33 (p 0.386)receipt 9705
Swarm cases
receipt 9705: NCAPD2 in dopamine neurons, braak
- power
- full sample -0.09 (p 0.709, n 18), 95% CI -0.54 to +0.39. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.04 (p 0.888, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.09 (p 0.728, n 18). could be the mix.
- skeptic
- leave-one-out range -0.26 to -0.02, sign flips 0; without severely affected donors -0.09 (p 0.709, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.62 (p 0.0064, n 18) vs -0.09 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NCAPD2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up NCAPD2 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.32 p 0.248 (needs p < 2.2e-4)
Receipts
loading the receipts